Cardiotoxicity in Breast Cancer Chemotherapy
Author Information
Author(s): Erselcan T, Kairemo K J A, Wiklund T A, Hernberg M, Blomqvist C P, Tenhunen M, Bergh J, Joensuu H
Primary Institution: Helsinki University Central Hospital
Hypothesis
Does dose-escalated FEC chemotherapy cause more myocardial damage compared to standard chemotherapy regimens?
Conclusion
Subclinical cardiac damage from standard-dose FEC followed by high-dose chemotherapy is less than that from dose-escalated FEC.
Supporting Evidence
- Cardiac antimyosin antibody uptake was higher in patients treated with dose-escalated FEC compared to those treated with high-dose CTCb.
- The difference in cardiac damage between high-dose CTCb and standard CMF was not significant.
- A linear association was found between the cumulative dose of epirubicin and cardiac antimyosin uptake.
Takeaway
This study found that some breast cancer treatments can hurt the heart, but one type of treatment is worse than others.
Methodology
Patients received different chemotherapy regimens, and cardiac damage was assessed using antimyosin scintigraphy.
Participant Demographics
Patients with breast cancer receiving different chemotherapy regimens.
Statistical Information
P-Value
p<0.001
Confidence Interval
1.36–2.24 for group I, 1.20–1.82 for group II, 1.15–1.68 for group III
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website